1 Min Read
Jan 4 (Reuters) - Enanta Pharmaceuticals Inc
* FDA grants fast track designation to Enanta’s FXR Agonist candidate, EDP-305, for the treatment of nash with liver fibrosis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.